A follow-up question MM. Do you think there is even a remote possibility that the medical and pharma industry (currently running scared from their involvement in the opioid crisis) may be at some point required to look for alternatives, particularly if there is reasonable to strong evidence of superior patient outcomes with no addictive properties? I'll give you a tip....think of it from a professional indemnity perspective
A follow-up question MM. Do you think there is even a remote...
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.005(2.00%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $187.1K | 755.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 47906 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 13363 | 1 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |